# Omitting CTV for Primary Tumor in LS-SCLC

Source: https://onco.cc/trials/nct07008716/  
OnCo record `nct07008716` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of etoposide, carboplatin and cisplatin in lung cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Omitting CTV for Primary Tumor in LS-SCLC is a phase 3, randomised interventional study registered as NCT07008716 by Sun Yat-sen University, with a registry enrolment figure of 852 participants, started 2025-06-03 and due to reach its primary completion in 2027-12-31. Interventions recorded: Radiation Therapy; Etoposide + carboplatin; Etoposide + cisplatin; Creating CTV for primary tumor; prophylactic cranial irradiation (PCI). Conditions listed: SCLC, Limited Stage; Radiation Exposure; Radiotherapy Side Effect; Progression. Primary outcome: Local progression free survival; Severe toxicity free survival. Lung eligibility wording from the registry: "Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metastasis;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07008716
- Phase: 3
- Setting: Omission of Clinical Target Volume (CTV) for Primary Tumors in Limited-Stage Small Cell Lung Cancer: A Prospective Multicenter Randomized Controlled Trial
- Sponsor: Sun Yat-sen University
- Enrolled: 852

## Sources

- ClinicalTrials.gov NCT07008716: https://clinicaltrials.gov/study/NCT07008716

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07008716.json